IS8217A - Bætt framleiðsla rósúvastatínkalsíumsalts - Google Patents

Bætt framleiðsla rósúvastatínkalsíumsalts

Info

Publication number: IS8217A
Authority: IS; Iceland
Prior art keywords: calcium salt; improved production; rosuvastatin calcium; rosuvastatin; production
Prior art date: 2003-06-05

Application number

IS8217A

Other languages

English (en)

Other versions

IS2751B (is

Inventor

Norman Crabb Jeffrey

Horbury John

Philip Taylor Nigel

Original Assignee

Astrazeneca Uk Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-06-05

Filing date

2006-01-02

Publication date

2006-01-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33512687&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS8217(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-01-02 Application filed by Astrazeneca Uk Limited filed Critical Astrazeneca Uk Limited

2006-01-02 Publication of IS8217A publication Critical patent/IS8217A/is

2011-09-15 Publication of IS2751B publication Critical patent/IS2751B/is

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IS8217A 2003-06-05 2006-01-02 Bætt@framleiðsla@rósúvastatínkalsíumsalts IS2751B (is)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB0312896.4A GB0312896D0 (en)	2003-06-05	2003-06-05	Chemical process
GBGB0324793.9A GB0324793D0 (en)	2003-06-05	2003-10-24	Chemical process
PCT/GB2004/002373 WO2004108691A1 (en)	2003-06-05	2004-06-03	Improved production of rosuvastatin calcium salt

Publications (2)

Publication Number	Publication Date
IS8217A true IS8217A (is)	2006-01-02
IS2751B IS2751B (is)	2011-09-15

Family

ID=33512687

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS8217A IS2751B (is)	2003-06-05	2006-01-02	Bætt@framleiðsla@rósúvastatínkalsíumsalts

Country Status (25)

Country	Link
US (1)	US8063213B2 (is)
EP (1)	EP1633727B1 (is)
JP (1)	JP4651615B2 (is)
KR (1)	KR101099934B1 (is)
CN (1)	CN100422157C (is)
AR (1)	AR044773A1 (is)
AT (1)	ATE464297T1 (is)
AU (1)	AU2004245291B2 (is)
BR (1)	BRPI0410922B8 (is)
CA (1)	CA2527314C (is)
CO (1)	CO5640116A2 (is)
DE (1)	DE602004026576D1 (is)
ES (1)	ES2341858T3 (is)
GB (2)	GB0312896D0 (is)
IL (1)	IL172075A (is)
IS (1)	IS2751B (is)
MX (1)	MXPA05013128A (is)
MY (1)	MY140820A (is)
NO (1)	NO332971B1 (is)
NZ (1)	NZ543962A (is)
RU (1)	RU2361864C2 (is)
SA (1)	SA04250223B1 (is)
TW (1)	TWI341310B (is)
UY (1)	UY28341A1 (is)
WO (1)	WO2004108691A1 (is)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0003305D0 (en)	2000-02-15	2000-04-05	Zeneca Ltd	Pyrimidine derivatives
GB0011120D0 (en)	2000-05-09	2000-06-28	Avecia Ltd	Process
NL1015744C2 (nl)	2000-07-19	2002-01-22	Dsm Nv	Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
NZ531033A (en)	2001-07-13	2005-07-29	Astrazeneca Uk Ltd	Preparation of a 2-(N-methyl-N-methanesulfonylamino)pyrimidine compound or analogous aminopyrimidine compounds
EP1323717A1 (en)	2001-12-27	2003-07-02	Dsm N.V.	Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
EP1375493A1 (en)	2002-06-17	2004-01-02	Dsm N.V.	Process for the preparation of an dioxane acetic acid ester
GB0218781D0 (en)	2002-08-13	2002-09-18	Astrazeneca Ab	Chemical process
WO2004054986A2 (en)	2002-12-16	2004-07-01	Astrazeneca Uk Limited	Process for the preparation of pyrimidine compounds
GB0312896D0 (en)	2003-06-05	2003-07-09	Astrazeneca Ab	Chemical process
UY28501A1 (es)	2003-09-10	2005-04-29	Astrazeneca Uk Ltd	Compuestos químicos
GB0322552D0 (en)	2003-09-26	2003-10-29	Astrazeneca Uk Ltd	Therapeutic treatment
GB0324791D0 (en) *	2003-10-24	2003-11-26	Astrazeneca Ab	Chemical process
US7851624B2 (en)	2003-12-24	2010-12-14	Teva Pharamaceutical Industries Ltd.	Triol form of rosuvastatin and synthesis of rosuvastatin
EP1737828A1 (en) *	2004-01-19	2007-01-03	Ranbaxy Laboratories Limited	Amorphous magnesium salts of rosuvastatin
GB0428328D0 (en)	2004-12-24	2005-02-02	Astrazeneca Uk Ltd	Chemical process
MX2007010138A (es) *	2005-02-22	2007-09-27	Teva Pharma	Preparacion de rosuvastatina.
CN101203496B (zh)	2005-06-24	2011-04-20	力奇制药公司	纯的无定形瑞舒伐他汀钙的制备方法
CZ299215B6 (cs) *	2005-06-29	2008-05-21	Zentiva, A. S.	Zpusob výroby hemivápenaté soli (E)-7-[4-(4-fluorofenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxy-6-heptenovékyseliny
GB0514078D0 (en) *	2005-07-08	2005-08-17	Astrazeneca Uk Ltd	Chemical process
MX2007004423A (es) *	2005-08-16	2007-06-14	Teva Pharma	Calcio de rosuvastatina con bajo contenido de sal.
BRPI0605917A2 (pt)	2005-08-16	2009-05-26	Teva Pharma	intermediário cristalino de rosuvastatina
HU227696B1 (en) *	2006-04-13	2011-12-28	Egyt Gyogyszervegyeszeti Gyar	Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
EP2024341B1 (en)	2006-05-03	2015-12-02	MSN Laboratories Private Limited	Novel process for statins and its pharmaceutically acceptable salts thereof
ES2567171T3 (es)	2006-10-09	2016-04-20	Msn Laboratories Private Limited	Nuevo procedimiento para la preparación de estatinas y sus sales farmacéuticamente aceptables
TW200831469A (en) *	2006-12-01	2008-08-01	Astrazeneca Uk Ltd	Chemical process
HU230981B1 (hu) *	2007-10-12	2019-08-28	Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság	Eljárás rosuvastatin só előállítására
WO2009143776A1 (zh)	2008-05-27	2009-12-03	常州制药厂有限公司	瑞舒伐他汀钙盐的制备方法及其中间体
EP2138165A1 (en)	2008-06-27	2009-12-30	KRKA, tovarna zdravil, d.d., Novo mesto	Pharmaceutical composition comprising a statin
PL2309992T3 (pl)	2008-06-27	2018-05-30	Krka, Tovarna Zdravil, D.D., Novo Mesto	Kompozycja farmaceutyczna zawierająca statynę
US20110245285A1 (en) *	2008-09-09	2011-10-06	Biocon Limited	Process for preparation of rosuvastatin acetonide calcium
EP2373609B1 (en)	2008-12-19	2013-10-16	KRKA, D.D., Novo Mesto	Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
EP2327682A1 (en)	2009-10-29	2011-06-01	KRKA, D.D., Novo Mesto	Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
EP2387561A4 (en)	2009-01-19	2012-07-25	Msn Lab Ltd	IMPROVED PROCESS FOR THE PREPARATION OF HIGH-PURITY (3R, 5S) -7-β-CYCLOPROPYL-4- (4-FLUOROPHENYL) QUINOLIN-3-YL-3,5-DIHYDROXY-6 (E) -HEPTENOIC ACID, INCLUDING ITS PHARMACEUTICALLY ACCEPTABLE SALTS
WO2011086584A2 (en)	2010-01-18	2011-07-21	Msn Laboratories Limited	Improved process for the preparation of amide intermediates and their use thereof
WO2011132172A1 (en)	2010-04-23	2011-10-27	Ranbaxy Laboratories Limited	NOVEL INTERMEDIATES FOR THE PREPARATION OF HMG-CoA REDUCTASE INHIBITORS
WO2012011129A2 (en) *	2010-07-22	2012-01-26	Msn Laboratories Limited	Novel polymorph of bis[(e)-7-[4-(4-fluorophenyl)-6-iso-propyl-2-[methyl (methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt
CN105753834B (zh) *	2016-03-25	2018-08-21	河南师范大学	一种瑞舒伐他汀钙关键手性中间体的合成方法

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4645858A (en)	1982-03-22	1987-02-24	G. D. Searle & Co.	Pentanedioic acid derivatives
DE3741509A1 (de)	1987-12-08	1989-06-22	Hoechst Ag	Verfahren zur herstellung optisch aktiver 3-desmethylmevalonsaeurederivate sowie zwischenprodukte
ZA891696B (en)	1988-10-06	1990-11-28	Sandoz Ltd	Pyrimidinyl-substituted hydroxyacids,lactones and esters and pharmaceutical compositions containing them
US5026698A (en)	1988-11-02	1991-06-25	Nissan Chemical Industries, Ltd.	Thienopyridine type mevalonolactones
JP2648897B2 (ja) *	1991-07-01	1997-09-03	塩野義製薬株式会社	ピリミジン誘導体
WO1993008823A1 (en)	1991-11-06	1993-05-13	Tanabe Seiyaku Co., Ltd.	Guanidinyl and related cell adhesion modulation compounds
US5278313A (en)	1992-03-27	1994-01-11	E. R. Squibb & Sons, Inc.	Process for the preparation of 1,3-dioxane derivatives useful in the preparation of HMG-COA reductase inhibitors
DE59307409D1 (de)	1992-07-02	1997-10-30	Hoechst Ag	Verfahren zur Herstellung von (3R,5S)6-Hydroxy-3,5-0-isopropyliden-3,5-dihydroxy-hexansäure-tert.-butylester
EP0848705B1 (en)	1995-07-17	2001-11-07	Warner-Lambert Company	Crystalline r-(r,r)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- (phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
US6278001B1 (en)	1995-11-28	2001-08-21	L'oréal	Method for preparing (+) compactin and (+) mevinolin analog compounds having a β-hydroxy-δ-lactone grouping
FR2741620B1 (fr)	1995-11-28	1997-12-26	Oreal	Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline
DK0907639T3 (da)	1996-06-24	2003-06-23	Novartis Ag	Polymorfe forbindelser
SI20327B (sl)	1998-12-10	2015-02-27	Kaneka Corporation	Postopek za pripravo simvastatina
GB9900339D0 (en) *	1999-01-09	1999-02-24	Zeneca Ltd	Chemical compounds
GB9903472D0 (en)	1999-02-17	1999-04-07	Zeneca Ltd	Chemical process
WO2001022962A1 (en)	1999-09-30	2001-04-05	Merck & Co., Inc.	Anti-hypercholesterolemic drug combination
HUP0203257A3 (en)	1999-11-17	2003-05-28	Teva Pharma	Polymorphic forms of atorvastatin calcium, process for their preparations and pharmaceutical compositions containing them
GB0001621D0 (en)	2000-01-26	2000-03-15	Astrazeneca Ab	Pharmaceutical compositions
GB0003305D0 (en)	2000-02-15	2000-04-05	Zeneca Ltd	Pyrimidine derivatives
WO2001072706A1 (en)	2000-03-28	2001-10-04	Biocon India Limited	Synthesis of [r-(r,r)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
GB0011120D0 (en)	2000-05-09	2000-06-28	Avecia Ltd	Process
GB0011163D0 (en)	2000-05-10	2000-06-28	Astrazeneca Ab	Chemical compound
NL1015744C2 (nl)	2000-07-19	2002-01-22	Dsm Nv	Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
KR20030059173A (ko)	2000-10-05	2003-07-07	비오갈 기오기스제르갸르 알티.	프라바스타틴 락톤과 에피-프라바스타틴을 실질적으로함유하지 않는 프라바스타틴 나트륨, 및 이를 포함하는조성물
US6777552B2 (en)	2001-08-16	2004-08-17	Teva Pharmaceutical Industries, Ltd.	Processes for preparing calcium salt forms of statins
CA2427255A1 (en)	2000-11-16	2002-06-06	Teva Pharmaceutical Industries Ltd.	Hydrolysis of [r(r,r)]-2-(4-fluorophenyl)-.beta.,.delta. -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide
IL156055A0 (en)	2000-11-30	2003-12-23	Teva Pharma	Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
NL1017548C2 (nl)	2001-03-09	2002-09-10	Synthon Bv	Een lactonisatie proces.
IN190564B (is)	2001-04-11	2003-08-09	Cadila Heathcare Ltd
HUP0401724A2 (hu)	2001-06-06	2004-12-28	Bristol-Myers Squibb Co.	Eljárás királis diol-szulfon és dihidroxi-sav típusú HMG CoA reduktáz inhibitorok előállítására
NZ531033A (en)	2001-07-13	2005-07-29	Astrazeneca Uk Ltd	Preparation of a 2-(N-methyl-N-methanesulfonylamino)pyrimidine compound or analogous aminopyrimidine compounds
CN100430405C (zh)	2001-08-16	2008-11-05	特瓦制药工业有限公司	制备他汀类的钙盐形式的方法
EP1423365A1 (en)	2001-08-22	2004-06-02	Ciba Specialty Chemicals Holding Inc.	Process for the preparation of indole derivatives
EP1465667A4 (en)	2001-09-24	2007-06-27	Merck & Co Inc	SCREENING AND SELECTION PROCEDURE FOR STATIN COMBINATIONS
EP1323717A1 (en)	2001-12-27	2003-07-02	Dsm N.V.	Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
KR100511533B1 (ko)	2002-04-09	2005-08-31	임광민	키랄 중간체, 그의 제조방법 및 그를 이용한 HMG-CoA환원저해제의 제조방법
AU2003228010A1 (en)	2002-05-21	2003-12-02	Ranbaxy Laboratories Limited	Process for the preparation of rosuvastatin
EP1375493A1 (en)	2002-06-17	2004-01-02	Dsm N.V.	Process for the preparation of an dioxane acetic acid ester
GB0218781D0 (en)	2002-08-13	2002-09-18	Astrazeneca Ab	Chemical process
EP1578733B1 (en)	2002-12-10	2011-03-09	Ranbaxy Laboratories Limited	Process for the preparation of rosuvastatin
WO2004054986A2 (en)	2002-12-16	2004-07-01	Astrazeneca Uk Limited	Process for the preparation of pyrimidine compounds
CA2520740C (en)	2003-04-11	2012-06-05	Lek Pharmaceuticals D.D.	Process for the preparation of amorphous calcium salt of atorvastatin
WO2004103977A2 (en)	2003-05-21	2004-12-02	Ciba Specialty Chemicals Holding Inc.	Process for the preparation of pyrimidine derivatives
GB0312896D0 (en)	2003-06-05	2003-07-09	Astrazeneca Ab	Chemical process
AU2003247327A1 (en)	2003-07-15	2005-01-28	Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S.	Process for the preparation of amortphous atorvastatin calcium without interconversion of any crystalline form
EP1562912A2 (en)	2003-08-28	2005-08-17	Teva Pharmaceutical Industries Limited	Process for preparation of rosuvastatin calcium
UY28501A1 (es)	2003-09-10	2005-04-29	Astrazeneca Uk Ltd	Compuestos químicos
GB0321827D0 (en)	2003-09-18	2003-10-15	Astrazeneca Uk Ltd	Chemical compounds
GB0322552D0 (en)	2003-09-26	2003-10-29	Astrazeneca Uk Ltd	Therapeutic treatment
CN1886383A (zh)	2003-10-22	2006-12-27	兰贝克赛实验室有限公司	无定形罗苏伐他汀钙的制备方法
GB0324791D0 (en)	2003-10-24	2003-11-26	Astrazeneca Ab	Chemical process
DE10352659B4 (de)	2003-11-11	2007-09-13	Ratiopharm Gmbh	Verfahren zur Herstellung von Statinen und Tetrahydropyranonderivate zur Verwendung in dem Verfahren
CA2546701C (en)	2003-11-24	2010-07-27	Teva Pharmaceutical Industries Ltd.	Crystalline ammonium salts of rosuvastatin
TWI351958B (en)	2003-12-02	2011-11-11	Teva Pharma	Degradation products as reference standard for ana
WO2005054207A1 (en)	2003-12-04	2005-06-16	Glenmark Pharmaceuticals Limited	Process for the preparation of pyrimidine derivatives
WO2005063728A2 (en)	2003-12-24	2005-07-14	Teva Pharmaceutical Industries Ltd.	Process for preparation of statins with high syn to anti ratio
CZ200486A3 (cs)	2004-01-16	2005-08-17	Zentiva, A.S.	Způsob výroby hemivápenaté soli (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxy-6-heptenové kyseliny
EP1737828A1 (en)	2004-01-19	2007-01-03	Ranbaxy Laboratories Limited	Amorphous magnesium salts of rosuvastatin
EP1709008A1 (en)	2004-01-19	2006-10-11	Ranbaxy Laboratories Limited	Salts of hmg-coa reductase inhibitors and use thereof
US7241800B2 (en)	2004-03-17	2007-07-10	Mai De Ltd.	Anhydrous amorphous form of fluvastatin sodium
GB0406757D0 (en)	2004-03-26	2004-04-28	Avecia Ltd	Process and compounds
US7161004B2 (en)	2004-06-21	2007-01-09	Dr. Reddy's Laboratories Limited	Processes to produce intermediates for rosuvastatin
EP1673351A1 (en)	2004-07-13	2006-06-28	Teva Pharmaceutical Industries Ltd.	A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
EP1797046A2 (en)	2004-09-27	2007-06-20	Ranbaxy Laboratories Limited	Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium
GB0428328D0 (en)	2004-12-24	2005-02-02	Astrazeneca Uk Ltd	Chemical process
EP1844021A1 (en)	2005-01-31	2007-10-17	Ciba Specialty Chemicals Holding Inc.	Crystalline forms of rosuvastatin calcium salt
CA2498978A1 (en)	2005-02-28	2006-08-28	Apotex Pharmachem Inc.	An improved process for the preparation of atorvastatin and intermediates
GB0514078D0 (en)	2005-07-08	2005-08-17	Astrazeneca Uk Ltd	Chemical process
TW200831469A (en)	2006-12-01	2008-08-01	Astrazeneca Uk Ltd	Chemical process

2003
- 2003-06-05 GB GBGB0312896.4A patent/GB0312896D0/en not_active Ceased
- 2003-10-24 GB GBGB0324793.9A patent/GB0324793D0/en not_active Ceased
2004
- 2004-05-24 TW TW093114667A patent/TWI341310B/zh not_active IP Right Cessation
- 2004-06-02 UY UY28341A patent/UY28341A1/es not_active Application Discontinuation
- 2004-06-03 ES ES04735910T patent/ES2341858T3/es not_active Expired - Lifetime
- 2004-06-03 WO PCT/GB2004/002373 patent/WO2004108691A1/en not_active Ceased
- 2004-06-03 EP EP04735910A patent/EP1633727B1/en not_active Expired - Lifetime
- 2004-06-03 AU AU2004245291A patent/AU2004245291B2/en not_active Expired
- 2004-06-03 RU RU2005138370/04A patent/RU2361864C2/ru active
- 2004-06-03 CA CA2527314A patent/CA2527314C/en not_active Expired - Fee Related
- 2004-06-03 BR BRPI0410922A patent/BRPI0410922B8/pt active IP Right Grant
- 2004-06-03 DE DE602004026576T patent/DE602004026576D1/de not_active Expired - Lifetime
- 2004-06-03 KR KR1020057023329A patent/KR101099934B1/ko not_active Expired - Lifetime
- 2004-06-03 AT AT04735910T patent/ATE464297T1/de not_active IP Right Cessation
- 2004-06-03 MX MXPA05013128A patent/MXPA05013128A/es active IP Right Grant
- 2004-06-03 NZ NZ543962A patent/NZ543962A/en not_active IP Right Cessation
- 2004-06-03 US US10/558,390 patent/US8063213B2/en active Active
- 2004-06-03 MY MYPI20042138A patent/MY140820A/en unknown
- 2004-06-03 CN CNB2004800154822A patent/CN100422157C/zh not_active Expired - Lifetime
- 2004-06-03 JP JP2006508394A patent/JP4651615B2/ja not_active Expired - Lifetime
- 2004-06-04 AR ARP040101944A patent/AR044773A1/es unknown
- 2004-07-14 SA SA04250223A patent/SA04250223B1/ar unknown
2005
- 2005-11-21 IL IL172075A patent/IL172075A/en active IP Right Grant
- 2005-12-02 CO CO05122683A patent/CO5640116A2/es unknown
- 2005-12-05 NO NO20055730A patent/NO332971B1/no not_active IP Right Cessation
2006
- 2006-01-02 IS IS8217A patent/IS2751B/is unknown

Also Published As

Publication number	Publication date
RU2361864C2 (ru)	2009-07-20
NZ543962A (en)	2008-09-26
KR101099934B1 (ko)	2011-12-28
MY140820A (en)	2010-01-29
TW200510337A (en)	2005-03-16
ATE464297T1 (de)	2010-04-15
WO2004108691A1 (en)	2004-12-16
DE602004026576D1 (de)	2010-05-27
CN1798741A (zh)	2006-07-05
HK1087405A1 (en)	2006-10-13
CA2527314A1 (en)	2004-12-16
NO20055730D0 (no)	2005-12-05
AR044773A1 (es)	2005-10-05
JP2006526602A (ja)	2006-11-24
BRPI0410922B8 (pt)	2021-05-25
EP1633727A1 (en)	2006-03-15
US20080221323A1 (en)	2008-09-11
BRPI0410922A (pt)	2006-06-27
AU2004245291A1 (en)	2004-12-16
NO20055730L (no)	2005-12-27
NO332971B1 (no)	2013-02-11
BRPI0410922B1 (pt)	2016-02-23
JP4651615B2 (ja)	2011-03-16
CO5640116A2 (es)	2006-05-31
CN100422157C (zh)	2008-10-01
IS2751B (is)	2011-09-15
RU2005138370A (ru)	2006-07-10
UY28341A1 (es)	2005-01-31
ES2341858T3 (es)	2010-06-29
GB0312896D0 (en)	2003-07-09
TWI341310B (en)	2011-05-01
SA04250223B1 (ar)	2008-12-23
KR20060017848A (ko)	2006-02-27
EP1633727B1 (en)	2010-04-14
MXPA05013128A (es)	2006-03-16
AU2004245291B2 (en)	2008-02-14
CA2527314C (en)	2012-02-21
IL172075A (en)	2011-06-30
GB0324793D0 (en)	2003-11-26
US8063213B2 (en)	2011-11-22

Publication	Publication Date	Title
IS8217A (is)	2006-01-02	Bætt framleiðsla rósúvastatínkalsíumsalts
IS7728A (is)	2005-03-08	Aðferð til að framleiða kalsíumsalt rósuvastatíns
NL301158I2 (nl)	2022-05-25	Relugolix of een zout daarvan
CY2019045I2 (el)	2020-05-29	Παραγωγο 2-ακυλαμινοθειαζολης ή αλας αυτου
NL350091I2 (nl)	2019-05-15	Cyantraniliprole of een zout daarvan
NL300885I2 (nl)	2022-02-24	Irinotecansucrosofaatzout
MA28802B1 (fr)	2007-08-01	Utilisations therapeutiques d'inhibiteurs de rtp801
FIC20150014I1 (fi)	2015-03-12	Fluralaneeri tai sen suola
IL173858A0 (en)	2006-07-05	Process for preparation of rosuvastatin calcium
EP1788874A4 (en)	2010-11-24	5-AZACYTIDINE SALTS
ATE428701T1 (de)	2009-05-15	Kristalline form von bisä(e)-7-ä4-(4-fluorphenyl)-6-isopropyl-2-
DE602005027308D1 (de)	2011-05-19	Stabile salze von olanzapin
NO20043660L (no)	2004-10-12	Salter av valsartan
EP1660436A4 (en)	2006-11-22	cathepsin inhibitors
NO20050118D0 (no)	2005-01-10	Substituerte fenylsulfonamidinhibitorer av beta-amyolid produksjon
NO20052474D0 (no)	2005-05-23	Amort form av esomeprazolsalter
EP1764075A4 (en)	2010-08-04	HAMMER OF TISSUE FACTORING
IS8399A (is)	2006-04-05	Form fjölgervings 3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólíns
IS8321A (is)	2006-02-22	Stöðug afbrigði tegaseródvetnismaleats
ATE499348T1 (de)	2011-03-15	Stabiler polymorph von bifeprunoxmesilat
IS7477A (is)	2004-09-30	Aðferð við framleiðslu sýrusalts af gemifloxasíni
IS7963A (is)	2005-07-28	Efnasambönd með hamlandi virkni gegn prólýlólígópeptíðasa
DE602004022100D1 (de)	2009-09-03	Stimulationshilfe
DE602004030633D1 (de)	2011-02-03	Reinigung von Amidderivaten
EE00430U1 (et)	2004-04-15	Soolakamber